All In Biotech

Drug Trial Radar · NCT05592990

A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

A Two Part, Randomized, Participant and Investigator-blinded, 2-arm, Parallel-design, Placebo-controlled Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles on Tendon Regeneration in Patients With Achilles Tendinopathy

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Jun 14, 2023

Primary completion

Feb 3, 2026

Study completion Feb 3, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure local and systemic safety and tolerability as well as improvement of Achilles tendon mechanical properties after a single peritendon injection of NGI226 MP in comparison to placebo MP in patients with mid-portion Achilles tendinopathy.

Conditions

  • Achilles Tendinopathy

Interventions

  • NGI226Drug

    NGI226 MP

  • PlaceboDrug

    Placebo MP

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with AEs and SAEsTime frame: Up to Day 169 (End of Study)

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Tucson Orthopedic Institute PC

    Tucson, Arizona

  • Advanced Research LLC

    Deerfield Beach, Florida

  • Houston Methodist Hospital

    Houston, Texas

  • Novartis Investigative Site

    Caluire-et-Cuire, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hamburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.